Obtaining Informed Consent from More Patients Than the Target Enrollment
RIBOMIC Inc.
umedaptanib pegol (RBM-007), a domestic Phase III clinical trial for achondroplasia (WAKABA trial)
Strong expectations for our ACH drug candidate amid ongoing development of multiple treatments for ACH (the company's view)
No impact (full-year results for the fiscal year ending March 2027)
Full year ending March 2027 (no impact on results from this matter)
This matter will have no impact on full-year results for the fiscal year ending March 2027.
For patients who have provided consent, eligibility under the inclusion criteria and other requirements will be confirmed. Patients receiving existing drug therapy will proceed to enrollment in the trial after completing the prescribed washout period. We will steadily advance subject enrollment and focus on conducting the WAKABA trial.
| Item | Details |
|---|---|
| Event name | Obtaining Informed Consent from More Patients Than the Target Enrollment |
| Date of occurrence | 22 October 2026 (the date the company announced this matter; the date on which consent exceeding the target was obtained is Not disclosed) |
| Date recognized / date notice received | 22 October 2026 (date of announcement) |
| Subject Entity | RIBOMIC Inc. |
| Target Locations / Products | umedaptanib pegol (RBM-007), a domestic Phase III clinical trial for achondroplasia (WAKABA trial) |
| Cause | Strong expectations for our ACH drug candidate amid ongoing development of multiple treatments for ACH (the company's view) |
| Amount of Impact on Business Performance | No impact (full-year results for the fiscal year ending March 2027) |
| Accounting period in which recognized | Full year ending March 2027 (no impact on results from this matter) |
| Impact on Earnings Forecast | This matter will have no impact on full-year results for the fiscal year ending March 2027. |
| Outlook | For patients who have provided consent, eligibility under the inclusion criteria and other requirements will be confirmed. Patients receiving existing drug therapy will proceed to enrollment in the trial after completing the prescribed washout period. We will steadily advance subject enrollment and focus on conducting the WAKABA trial. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Amid ongoing development of multiple treatments for ACH, we view the ability to obtain consent from more patients than the target enrollment within a short period as demonstrating strong expectations for our ACH drug candidate.